A detailed history of Geode Capital Management, LLC transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 1,708,301 shares of ITCI stock, worth $144 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,708,301
Previous 1,686,173 1.31%
Holding current value
$144 Million
Previous $115 Million 8.16%
% of portfolio
0.01%
Previous 0.01%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$67.99 - $80.84 $1.5 Million - $1.79 Million
22,128 Added 1.31%
1,708,301 $125 Million
Q2 2024

Aug 09, 2024

SELL
$64.76 - $79.84 $24.6 Million - $30.3 Million
-379,125 Reduced 18.36%
1,686,173 $115 Million
Q1 2024

May 13, 2024

BUY
$64.37 - $75.65 $4.09 Million - $4.8 Million
63,507 Added 3.17%
2,065,298 $143 Million
Q4 2023

Feb 13, 2024

BUY
$46.37 - $73.65 $4.21 Million - $6.69 Million
90,769 Added 4.75%
2,001,791 $143 Million
Q3 2023

Nov 13, 2023

BUY
$52.09 - $64.1 $3.87 Million - $4.76 Million
74,265 Added 4.04%
1,911,022 $99.5 Million
Q2 2023

Aug 11, 2023

BUY
$54.67 - $66.44 $4.8 Million - $5.83 Million
87,739 Added 5.02%
1,836,757 $116 Million
Q1 2023

May 15, 2023

BUY
$43.8 - $56.99 $3.4 Million - $4.42 Million
77,581 Added 4.64%
1,749,018 $94.7 Million
Q4 2022

Feb 13, 2023

BUY
$44.07 - $54.45 $2.34 Million - $2.89 Million
53,127 Added 3.28%
1,671,437 $88.5 Million
Q3 2022

Nov 14, 2022

BUY
$42.7 - $59.99 $1.28 Million - $1.79 Million
29,911 Added 1.88%
1,618,310 $75.3 Million
Q2 2022

Aug 12, 2022

BUY
$43.0 - $65.64 $5.05 Million - $7.71 Million
117,442 Added 7.98%
1,588,399 $90.7 Million
Q1 2022

May 13, 2022

BUY
$38.74 - $62.09 $7.17 Million - $11.5 Million
185,143 Added 14.4%
1,470,957 $90 Million
Q4 2021

Feb 11, 2022

BUY
$35.2 - $53.42 $460,908 - $699,481
13,094 Added 1.03%
1,285,814 $67.3 Million
Q3 2021

Nov 12, 2021

BUY
$28.72 - $42.49 $560,556 - $829,319
19,518 Added 1.56%
1,272,720 $47.4 Million
Q2 2021

Aug 13, 2021

BUY
$29.3 - $44.5 $1.71 Million - $2.6 Million
58,449 Added 4.89%
1,253,202 $51.2 Million
Q1 2021

May 12, 2021

BUY
$30.8 - $39.51 $2.67 Million - $3.43 Million
86,757 Added 7.83%
1,194,753 $40.5 Million
Q4 2020

Feb 12, 2021

BUY
$23.34 - $32.22 $2.44 Million - $3.37 Million
104,632 Added 10.43%
1,107,996 $35.2 Million
Q3 2020

Nov 13, 2020

BUY
$17.61 - $31.86 $2.82 Million - $5.11 Million
160,340 Added 19.02%
1,003,364 $25.7 Million
Q2 2020

Aug 13, 2020

BUY
$14.35 - $26.64 $522,655 - $970,282
36,422 Added 4.52%
843,024 $21.6 Million
Q1 2020

May 14, 2020

BUY
$12.31 - $33.12 $2.06 Million - $5.53 Million
167,104 Added 26.13%
806,602 $12.4 Million
Q4 2019

Feb 13, 2020

SELL
$7.26 - $38.49 $93,457 - $495,481
-12,873 Reduced 1.97%
639,498 $21.9 Million
Q3 2019

Nov 12, 2019

BUY
$7.47 - $14.03 $59,438 - $111,636
7,957 Added 1.23%
652,371 $4.87 Million
Q2 2019

Aug 14, 2019

BUY
$10.65 - $14.29 $338,670 - $454,422
31,800 Added 5.19%
644,414 $8.36 Million
Q1 2019

May 14, 2019

BUY
$10.9 - $14.09 $960,867 - $1.24 Million
88,153 Added 16.81%
612,614 $7.46 Million
Q4 2018

Feb 13, 2019

BUY
$10.36 - $20.96 $265,091 - $536,324
25,588 Added 5.13%
524,461 $5.97 Million
Q3 2018

Nov 13, 2018

BUY
$17.77 - $22.9 $528,728 - $681,366
29,754 Added 6.34%
498,873 $10.8 Million
Q2 2018

Aug 14, 2018

BUY
$17.33 - $23.4 $898,785 - $1.21 Million
51,863 Added 12.43%
469,119 $8.29 Million
Q1 2018

May 15, 2018

BUY
$15.16 - $25.49 $243,499 - $409,420
16,062 Added 4.0%
417,256 $8.78 Million
Q4 2017

Feb 13, 2018

BUY
$14.27 - $16.79 $913,351 - $1.07 Million
64,005 Added 18.98%
401,194 $5.81 Million
Q3 2017

Nov 14, 2017

BUY
$10.77 - $22.1 $545,597 - $1.12 Million
50,659 Added 17.68%
337,189 $5.32 Million
Q2 2017

Aug 14, 2017

BUY
N/A
286,530
286,530 $3.56 Million

Others Institutions Holding ITCI

About Intra-Cellular Therapies, Inc.


  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $7.94B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.